+44 20 8123 2220
info@marketpublishers.com

Enanta- It is just the beginning of good news

https://marketpublishers.com/r/E4BFA4010D0EN.html
Date: November 2013
Pages: 2
Price: US$ 90.00 (Single User License)
ID: E4BFA4010D0EN

Abstracts

ENTA presented positive SVR12 data of SAPPHIRE-I –oral regimen (ENTA's /ABT-450 boosted Abbvie's ritonavir, ABT-267 and ABT-333) plus ribavirin where SVR12 rates were 95% in patients with HCV genotype 1a infection (n=322) and 98% in patients with HCV genotype 1b infection (n=151). This is data from the first of six Phase III HCV trial of ENTA/AbbVie's using its oral IFN free regimen. With More data to be announced in the next six months from other ongoing trials (Table 1) and regulatory filing in 2nd half of 2014 we expect ENTA shares to appreciate further. We are positive on the PhIII study outcome and approval by 2015.

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Enanta- It is just the beginning of good news
Product link: https://marketpublishers.com/r/E4BFA4010D0EN.html
Price: US$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/E4BFA4010D0EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970